{
  "id": 6645443,
  "title": "Study Warns on Venetoclax in Double-Hit Lymphoma",
  "url": "https://urgent.news/2026/09/10/study-warns-on-venetoclax-in-double-hit-lymphoma",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-10T20:37:58.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/hematologyoncology/lymphoma/122957"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Adding the BCL2 inhibitor venetoclax (Venclexta) to chemoimmunotherapy led to worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma, phase II results from a randomized trial showed. Median...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}